Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
Screening tests for Alzheimer's disease lack sensitivity and specificity. We developed the AD8, a brief dementia screening interview validated against clinical and cognitive evaluations, as an improvement over current screening methods. Because insufficient follow-up has occurred to validate the AD8 against the neuropathologic findings of Alzheimer's disease, we investigated whether AD8 scores correspond to impairment in episodic memory testing and changes in biomarkers of Alzheimer's disease (cerebrospinal fluid and amyloid imaging with Pittsburgh compound B) characteristic of symptomatic Alzheimer's disease. We also compared informant-based assessments with brief performance-based dementia screening measurements such as the Mini Mental State Exam. The sample (n = 257) had a mean age of 75.4 years with 15.1 years of education; 88.7% were Caucasian and 45.5% were male. The sample was divided into two groups based on their AD8 scores: those with a negative dementia screening test (AD8 score 0 or 1, n = 137) and those with a positive dementia screening test (AD8 score ≥2, n = 120). Individuals with positive AD8 scores had abnormal Pittsburgh compound B binding (P < 0.001) and cerebrospinal fluid biomarkers (P < 0.001) compared with individuals with negative AD8 scores. Individuals with positive AD8 tests and positive biomarkers scored in the impaired range on the Wechsler Logical Memory Story A (mean score 7.0 ± 4.5 for Pittsburgh compound B; mean score 7.6 ± 5.3 for cerebrospinal fluid amyloid beta protein 1-42). The AD8 area under the curve for Pittsburgh compound B was 0.737 (95% confidence interval: 0.64-0.83) and for cerebrospinal fluid amyloid beta protein 1-42 was 0.685 (95% confidence interval: 0.60-0.77) suggesting good discrimination. The AD8 had superior sensitivity in detecting early stages of dementia compared with the Mini Mental State Examination. The AD8 had a likelihood ratio of a positive test of 5.8 (95% confidence interval: 5.4-6.3) and likelihood ratio of a negative test of 0.04 (95% confidence interval: 0.03-0.06), increasing the pre-test probability of an individual having symptomatic Alzheimer's disease. Individuals with AD8 scores of ≥2 had a biomarker phenotype consistent with Alzheimer's disease and lower performance on episodic memory tests, supporting a diagnosis of Alzheimer's disease. Informant-based assessments may be superior to performance-based screening measures such as the Mini Mental State Examination in corresponding to underlying Alzheimer's disease pathology, particularly at the earliest stages of decline. The use of a brief test such as the AD8 may improve strategies for detecting dementia in community settings where biomarkers may not be readily available, and may enrich clinical trial recruitment by increasing the likelihood that participants have underlying biomarker abnormalities.
Galvin
James E
JE
Alzheimer's Disease Research Centre, Washington University, St Louis, MO 63108, USA. james.galvin@nyumc.org
Fagan
Anne M
AM
Holtzman
David M
DM
Mintun
Mark A
MA
Morris
John C
JC
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis* / Q000453:epidemiology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D010054:Brief Psychiatric Rating Scale / Q000592:standards; D003704:Dementia / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D010641:Phenotype
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)
J Nutr Health Aging. 2009 Apr;13(4):373-5
19300885
J Gen Intern Med. 2002 Aug;17(8):646-9
12213147
Gerontologist. 1999 Aug;39(4):457-64
10495584
Neurology. 1984 Jul;34(7):939-44
6610841
Arch Neurol. 2009 Dec;66(12):1476-81
20008651
Lancet Neurol. 2010 Jan;9(1):119-28
20083042
Am J Psychiatry. 1983 Jun;140(6):734-9
6846631
Neurology. 1993 Nov;43(11):2412-4
8232972
Neurology. 2006 Dec 12;67(11):1942-8
17159098
Alzheimers Dement. 2008 Jan;4(1):38-48
18631949
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Neurobiol Aging. 2009 Jul;30(7):1026-36
19376612
Arch Neurol. 2009 Sep;66(9):1151-7
19752306
Alzheimers Dement. 2008 Sep;4(5):353-60
18790462
Am Fam Physician. 2001 Feb 15;63(4):703-13, 717-8
11237085
Arch Neurol. 2007 May;64(5):718-24
17502471
Neurology. 2006 Aug 8;67(3):467-73
16894109
Arch Neurol. 2007 May;64(5):725-30
17502472
Arch Neurol. 2005 May;62(5):758-65
15883263
EMBO Mol Med. 2009 Nov;1(8-9):371-80
20049742
Can J Psychiatry. 2002 Oct;47(8):723-33
12420650
Int Psychogeriatr. 2008 Oct;20(5):911-26
18533066
Lancet Neurol. 2007 Aug;6(8):734-46
17616482
Recent Pat CNS Drug Discov. 2009 Nov;4(3):160-81
19891597
Exp Neurol. 2010 Jun;223(2):334-46
19815015
Age Ageing. 2004 Sep;33(5):447-52
15217776
J Gerontol A Biol Sci Med Sci. 2004 Jun;59(6):M621-6
15215282
Ann Neurol. 2006 Mar;59(3):512-9
16372280
J Med Chem. 2003 Jun 19;46(13):2740-54
12801237
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):117-23
19484913
Nature. 2009 Oct 15;461(7266):916-22
19829371
Ann Neurol. 2009 Apr;65(4):403-13
19296504
Neurology. 2005 Aug 23;65(4):559-64
16116116
Arch Neurol. 2009 Dec;66(12):1469-75
20008650
Arch Neurol. 2009 Dec;66(12):1447-55
20008648
J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40
8784228
Neurology. 2008 Nov 25;71(22):1783-9
19029518
JAMA. 2009 Jul 22;302(4):385-93
19622817
JAMA. 2007 Jun 6;297(21):2391-404
17551132
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101
19474567
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):371-6
19561437
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
17132964
Neurology. 2006 Aug 8;67(3):446-52
16894106
Arch Neurol. 1988 Jan;45(1):31-2
3337672
Arch Neurol. 1998 Mar;55(3):326-35
9520006
Arch Neurol. 2001 Mar;58(3):397-405
11255443
J Am Geriatr Soc. 2004 May;52(5):822-7
15086669
Neuroimage. 2004 Oct;23(2):724-38
15488422
Exp Gerontol. 2010 Jan;45(1):5-14
19796673
Arch Neurol. 2009 Oct;66(10):1254-9
19822781
Neurology. 1988 Jun;38(6):900-3
3368071
Arch Neurol. 2007 Mar;64(3):343-9
17210801
Ann Neurol. 2004 Mar;55(3):306-19
14991808